Aims of the MOMENTUM Study
The MOMENTUM study is a complex registry, integrating clinical and technical patient data. The aim of the MOMENTUM study is to provide a data infrastructure to:
- Collect routine-care data for the evaluation of short- and long-term feasibility, safety, effectiveness, and toxicity of treatments on the MR-Linac. This also facilitates the evaluation of (early) cost-effectiveness of MR-Linac treatments.
- Aggregate technical patient data to further develop MR-Linac software algorithms that drive the online adaptive workflow aiming to maximize the benefits of MRgRT.
- Create a repository of anatomical and functional MR imaging data supporting Stage 0 of the R-IDEAL framework and aiming to further develop MRgRT.
MR-Linac Consortium and MOMENTUM
The MOMENTUM study was set up within the context of the international MR-Linac Consortium, which currently consists of over 80 international centers.
All participating Institutes’ Committees for the Protection of Human Subjects have approved the MOMENTUM study, and it has been registered at clinicaltrials.gov. The MOMENTUM study was aided by a professional public-private partnership manager (Lygature).
Twelve Tumor Site Groups (TSGs) were established within the Consortium: brain, bladder, breast, cervix, esophagus, liver, lung, oligometastases, oropharynx, pancreas, prostate, and rectal cancer. The TSGs are international, cancer site-specific expert panels aiming to develop and evaluate MR-guided treatment strategies. The main activities of these TSGs include designing preparatory studies and collaborative clinical trials that follow the R-IDEAL framework. As the MOMENTUM study is an ever-evolving and expanding project, both the number of participating centers as the number of TSGs are likely to increase.
Data Management Task Force (DMTF)
The MOMENTUM Data Management Task Force (DMTF) is charged with ensuring that data requests are processed according to the rules and procedures below but will not make judgments about research priorities or the soundness of any individual proposal.
The overall strategic direction of the Consortium is overseen by the Clinical Steering Committee (CSC) and Tumor Site Groups (TSG). The DMTF works in service of the CSC, TSGs and Consortium institutions to help facilitate the management of data, ensure the absence of overlapping / competing projects, and the general feasibility of proposals with regard to data availability and resources.